SECURITIES AND EXCHANGE COMMISSION
                          Washington, D.C.  20549

                                FORM 10-KSB

         [X]  ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE
                      SECURITIES EXCHANGE ACT OF 1934

      [  ]  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)  OF THE
                      SECURITIES EXCHANGE ACT OF 1934

               For the fiscal year ended: December 31, 2000

                     Commission File Number: 000-25523

                        ANONYMOUS DATA CORPORATION
           (Exact name of registrant as specified in our charter)

Nevada                                                 86-0857752
(State or other jurisdiction of                        (I.R.S. Employer
incorporation or organization)                         Identification No.)

2780 South Jones
Las Vegas, Nevada                                      89146
(Address of principal executive offices)               (Zip Code)

     Registrant's telephone number including area code: (702) 933-3713

        Securities registered pursuant to Section 12(b) of the Act:
                                   None

        Securities registered pursuant to Section 12(g) of the Act:
                      Common Stock, $0.001 par value
                             (Title of Class)

     Indicate  by  check  mark whether the registrant  (a)  has  filed  all
reports  required  to  be filed by Section 13 or 15(d)  of  the  Securities
Exchange  Act  of 1934 during the preceding 12 months (or for such  shorter
period that the registrant was required to file such reports), and (2)  has
been  subject to such filing requirements for the past 90 days.  Yes  X  No
_____

     Indicate by check mark if disclosure of delinquent filers pursuant  to
Item  405  of  Regulation  S-K is not contained herein,  and  will  not  be
contained,  to the best of registrant's knowledge, in definitive  proxy  or
information statements incorporated by reference in Part III of  this  Form
10-KSB or any amendment to this Form 10-K.  [     ]

     The number of shares of Common Stock, $0.001 par value, outstanding on
March   31,  2001,  was  12,895,303  shares,  held  by  approximately   119
stockholders.

<PAGE>

                        ANONYMOUS DATA CORPORATION
                        FOR THE FISCAL PERIOD ENDED
                             December 31, 2000

                              Index to Report
                              on Form 10-KSB


PART I                                                                 Page

Item      1.  Business                                                   2-6
Item      2.  Properties                                                   6
Item      3.  Legal Proceedings                                            6
Item      4.  Submission of Matters to a Vote of Security Holders          6

PART II

Item      5.  Market for Registrant's Common Equity
              and Related Stockholder Matters                              7
Item      6.  Management's Discussion and Analysis of Financial Condition
              and Results of Operation                                   7-9
Item      7.  Financial Statements and Supplementary Data                  9
Item      8.  Changes in and Disagreements With Accountants on Accounting
              and Financial Disclosure                                     9

PART III

Item      9.  Directors and Executive Officers of the Registrant        10-11
Item      10. Executive Compensation                                    11-13
Item      11. Security Ownership of Certain Beneficial
              Owners and Management                                        13
Item      12. Certain Relationships and Related Transactions            13-14

PART IV

Item      13. Exhibits, Financial Statement Schedules and
              Reports on Form 8-K                                          14

Signatures                                                                 15

<PAGE>

     This  form  10-KSB  contains  forward-looking  statements  within  the
meaning  of  the federal securities laws. These forward-looking  statements
are necessarily based on certain assumptions and are subject to significant
risks  and  uncertainties. These forward-looking statements  are  based  on
management's expectations as of the date hereof, and the Company  does  not
undertake  any  responsibility to update any of  these  statements  in  the
future.  Actual  future  performance and results  could  differ  from  that
contained in or suggested by these forward-looking statements as  a  result
of  factors set forth in this Form 10-KSB (including those sections  hereof
incorporated  by  reference  from other filings  with  the  Securities  and
Exchange Commission), in particular as set forth in "Business Risks"  under
Item  1  and set forth in the "Management's Discussion and Analysis"  under
Item 6.

    In  this  form 10-KSB references to "the Company", "ADC",  "we",  "us",
and "our" refer to ANONYMOUS DATA CORPORATION.

PART I

ITEM 1.   BUSINESS

Overview

     Anonymous  Data Corporation, a Nevada corporation formed in  November
1996,  is  a  development stage company engaged in the  business  of  data
management   using  a  biometric  identification  system.  The   biometric
identification  system;  (i) archives individual  data,  such  as  medical
educational  information,  for access by registered  users  through  rapid
sorting  using  scanning of a portion of their anatomy  as  a  preliminary
search  method;  and,  (ii) permits a second method of  identification  of
individuals volunteering for payment as plasma donors.

     We  are  currently  in  the process of searching  for  a  company  or
companies  with  which  we can either license or enter  into  a  strategic
alliance for the purpose of implementing our technology.

     We have obtained rights to a method of linking files of archived data
to  the  anatomy of an individual.  This method allows the search function
for  records to be more rapid and accurate and re-checked according to the
name  of  the  individual. We spent $4,568,136 during fiscal  2000  toward
research and development toward the refinement of our biometric individual
data identification system.

      Since  our inception, we have accumulated development stage operating
losses in excess of $6.5 million.  Our ability to complete certain research
projects  and  the development of equipment and software is dependent  upon
obtaining additional equity or debt financing. This condition could prevent
us  from  commencing business operations and continuing as a going concern.
Our  balance sheets have been prepared assuming we will continue as a going
concern,  and reflect no adjustments that might result from the outcome  of
this uncertainty.

     Because  of this uncertainty, no effect has been given in the balance
sheets to any future income tax benefit of the development stage operating
losses  recorded  to  date.   We  have a net operating  loss  carryforward
expiring in year 2020 available to reduce future income tax expense in the
amount of approximately $6,500,000.

Background

     The  term BIOMETRIC derives from the words body (BIO) and measurement
(METRIC).  The  science of biometrics has in recent  years  developed  the
technology to take a reading from a human (such as electronic  scan  of  a

<PAGE>

fingerprint,  iris  scan, facial recognition, palm  print,  voice  sample,
etc).  The electronic scan is then matched with the same biometric  marker
for  purposes  of  recognition and verification of  identity.  The  United
States  Patent  and Trademark Office has issued two U.S.  patents  to  Dr.
James  E.  Beecham, Chairman of the Company. The Patents,  Patent  Numbers
U.S.   5,876,926   [PCT/U.S.  98/16435])  and  U.S.  5,897,989   [PCT/U.S.
97/08015],  pertain  to  a  method, system and apparatus  that  permit  an
individual  to  submit biologic test specimens for medical  testing  under
biometric  identification.  The  system then  allows  for  the  subsequent
retrieval of test results from a computerized database utilizing the  same
biometric  personal  identification. These Patents have  been  exclusively
licensed  to  us from Dr. Beecham. - See "Certain Transactions  -  License
Agreement."

     The patented applications, in non-U.S. territories, may in theory  be
utilized  for  collecting  medical  specimens  in  containers  labeled  by
"biometric  index".  For example, a biometric index may be  obtained  from
the  scan of a fingerprint and/or the scan of the iris of the eye  of  the
specimen donor. After testing in a certified laboratory, the test data  is
stored electronically under linkage to that same personal biometric index.
Access  to  such "biometrically" stored information is controlled  by  the
re-scan of the specimen donor. Since viewing the data requires "unlocking"
the  computer file by scanning the same fingerprint and/or eye as was used
for  sending  the  specimen  to the lab in the  first  place,  our  system
provides  the secure protection of the donor's sample and limits  mistakes
that are sometimes made in the donation process.

Status of ADC's Products and Related Software

     We  initially  designed  our  ADCNET,  a  comprehensive  software  and
hardware system, to be generic to support all four of our intended  product
lines.  Namely,  1)  Court  Mandated Data  System,  2)  Infectious  Disease
Education  System,  3)  Plasma  Industry System,  and  4)  Medical  Records
Privacy/Genetics Data Security System.

     Each  of the four products named above would require a shared database
in  a  Local  Area Network (LAN) or a Wide Area Network (WAN)  environment.
Functionally,  each  of the systems has an "Enroll," "Recognize,"  "Print2D
bar code control label," and "Enter Results" options.

     During fiscal 2000 we beta tested ADCNET Version .5 as a "Pilot  Court
Data  System"  for the American Toxicology Institute, and Las Vegas  Family
Court.  This Version was a LAN between the Court and the Drug Testing  Lab.
Due  to technical difficulties and budget constraints within the Las  Vegas
Court  system,  our beta test has been terminated.  At  this  time  we  are
unable  to determine when, or if, we will be able to successfully implement
our ADCNET program within the Las Vegas Family Court or any other facility.

Strategic Alliances

     Our  success  has  always been dependent upon a  number  of  strategic
relationships  that  we  intend to enter into.  At  present,  we  have  not
established relationships with any particular entity. The amount and timing
of  resources which future strategic partners devote to assisting  us  will
not  be  within  our  control.  There can be no  assurance  that  strategic
partners  will  perform their obligations as expected or that  any  revenue
will  be  derived  from  strategic arrangements. If any  of  our  strategic
partners breaches or terminates an agreement with us or otherwise fails  to
conduct  its  collaborative activities in a timely manner, the development,
commercialization or marketing of the product which is the subject  of  the
agreement  may  be  delayed and we may be required to undertake  unforeseen
additional   responsibilities  or  to  devote   additional   resources   to
development, commercialization or market our products.

   The inability to enter into strategic relationships or the failure of  a
strategic partner to perform its obligations could have a material  adverse

<PAGE>

effect  on  our  business, financial condition and results  of  operations.
There  can  be  no  assurance that we will be able to negotiate  acceptable
strategic  agreements in the future, that the resulting relationships  will
be  successful  or  that we will continue to maintain or develop  strategic
relationships  or  to  replace strategic partners in  the  event  any  such
relationships  are  terminated.  Our  failure  to  maintain  any  strategic
relationship could materially and adversely affect our business,  financial
condition and results of operations.

Product Testing

     FDA   REGULATIONS  SPECIFY  THAT  PRODUCTS  AND  SOFTWARE  USED   FOR
EDUCATIONAL  PURPOSES  ONLY  ARE EXEMPT FROM FDA  REGULATION.  FURTHERMORE
PRODUCTS  THAT  DO NOT PROVIDE DIAGNOSIS OR TREATMENT ARE EXEMPT  AND  NOT
CONSIDERED  A MEDICAL DEVICE.  Any development of U.S. market products  in
line with the issued patents and related software programming domestically
will   take   note  of  FDA  regulations  in  anticipation  of  submitting
applications for approval to the FDA as necessary.

Suppliers

     Our  business strategy has been to combine proprietary technology  and
products  with  "best  of  class" technology and  products  and  design  an
integrated,  seamless product that takes advantage of the  quality  of  our
components.

     Hardware  Suppliers- Our products and services are not  dependent  on
any one supplier of hardware and will use any off-the-shelf IBM compatible
computer  available on the market today, i.e.-Compaq, DELL, Gateway,  etc.
We  do  not  foresee the acquisition of such equipment as  a  problem  and
supply should not affect our business in any way.

Software Suppliers

     We  primarily use software based on SQL database products designed by
VSOP of Nevada.

Competition

     We compete indirectly with certain companies which utilize biometrics
in   related  fields,  such  as  Sony  Corporation  and  Lockheed   Martin
Corporation,  which  have biometric systems on  the  market  that  are  in
current  use.  Other companies, such as NEC Technologies,  have  biometric
fingerprint   identification  systems  on   the   market   for   physician
identification when accessing computerized patient information rather than
a specific patient file.

      We are aware of medical data collection, storage and display systems
technology   entitled  "Medical  Image  Filing  Apparatus,"  and   "Health
Examination  Method  and  System Using Plural  Self-Test  Stations  and  a
Magnetic  Card."  These  systems  store medical  data  on  magnetic  media
contained on a card or film.

      Because  we  are  not a testing laboratory we do  not  compete  with
laboratory companies.

Developing and Changing Market

     The  market  for  archiving of medical data management is  continually
evolving  and  is  highly dependent upon changes in the  regulation  arena.
Concern  for privacy appears to be a favorable development for us.  Changes
in  technology and regulatory processes, however, may affect the demand for

<PAGE>

our  products, which in turn may cause existing companies in other  product
lines  to  shift  their emphasis to products similar to  our  services  and
products, thus increasing competition.

Intellectual Property

     Two  U.S.  patents  are currently licensed exclusively  to  us  (U.S.
5,876,926  [PCT/  US98/16435] and 5, 897, 989 [PCT/US97/08015])  from  our
Chairman,  James  E.  Beecham,  MD.  The  Exclusive  Licensee  Territorial
Agreement, as amended, is for all countries in the world under  terms  and
conditions  relating to payment of patent fees, use  of  the  license  and
payment  of  royalties.   These licenses are exclusive  and  non-revocable
until  May 14, 2016 assuming compliance of the parties with the terms.  We
are  required to produce at least $1 million in revenues within the  first
seven (7) years under the licenses or they will terminate. Pursuant to the
License  Agreement, a fee will be paid to Dr. Beecham in  the  form  of  a
royalty  of three percent (3%) of the first $10 million gross revenues  to
us  from  the  manufacture, use, sale or operation  of  the  Products  and
Services, two percent (2%) of gross revenues which exceed $10 million  but
are  less  than  $25 million and one percent (1%) of gross revenues  which
exceed $25 million. We consider these licensed patents to be valuable  and
of substantial commercial benefit.

     We  also seek to protect our intellectual property rights by limiting
access  to  the  distribution  of our software,  documentation  and  other
proprietary  information.  In  addition,  we  enter  into  confidentiality
agreements with our employees and certain customers, vendors and strategic
partners.  There can be no assurance that the steps taken by  us  in  this
regard  will be adequate to prevent misappropriation of our technology  or
that our competitors will not independently develop technologies that  are
substantially equivalent or superior to our technologies.

     By virtue of his agreement with us, Dr. Beecham is under no obligation
to assign or license to us any additional patents he may receive beyond the
initial  two U.S. patents already licensed by us. A first rights of license
provision  for  additional patents by Dr. Beecham in the  area  of  medical
biometrics  is  in  place in exchange for our promise to provide  funds  to
underwrite  the costs of additional patent filings and prosecution.   There
can  be no assurance that any patents, federal trademarks or services marks
will  be  granted, additional patents will be licensed or that the licensed
patents,  although  issued  by  the Patent and  Trademark  Office,  can  be
defended  or  will  permit  substantial  protection  for  our  services  or
products.

Government Approvals

     The  United States Food and Drug Administration (the "FDA"),  is  the
most  stringent regulatory agency for medical devices and claims  and  may
have  jurisdiction  over  one  or  more  of  our  services  and  products.
Exemptions  exist  for  non-diagnostic and  non-treatment  data  archiving
systems.  We expect that biometric-based information systems that  provide
archival  non-diagnostic,  non-treatment data, will  be  exempt.  However,
there  can  be  no  guarantee that the governmental regulations  will  not
change  in  the future. Governmental guidelines for universal and  special
precautions  for handling infectious disease material do not apply  to  us
since  we  are  a  medical  education  and  data  storage,  retrieval  and
dissemination service.  Neither can there be a guarantee that our products
or  services can successfully compete with those of other competitors,  or
that  the protection provided by the U.S. patents licensed by us  will  be
successful  in preventing competitors from offering services  or  products
similar  to  ours.  We further believe that certain of  our  products  and
services  may  not qualify for exemption without FDA pre-market  approval.
FDA  approval  should  be  expedited by our plans to  utilize  consultants
familiar  with  FDA procedures. There can be no guarantee,  however,  that
these approvals will be received in an expeditious manner.

<PAGE>

Employees

      As of December 31, 2000, we had 1 full time employee and 2 part time
employees.  All employees are located at our headquarters  in  Las  Vegas.
None of our employees are subject to any collective bargaining agreement.

      We  are dependent upon the services of James E. Beecham, MD, Chairman
of  the  Company  and President.  Our future success also  depends  on  our
ability  to  attract  and  retain  other  qualified  personnel,  for  which
competition is intense. The loss of Dr. Beecham or our inability to attract
and  retain other qualified employees, could have a material adverse effect
on us.

Additional Information

     We  are  subject  to the informational requirements of the  Securities
Exchange  Act  of  1934 (the "Exchange Act") and, in accordance  therewith,
will  file  reports,  proxy  statements  and  other  information  with  the
Commission.  Such  reports, proxy statements and other information  may  be
inspected  at  public reference facilities of the Commission  at  Judiciary
Plaza,  450  Fifth  Street  N.W., Washington D.C. 20549;  Northwest  Atrium
Center,  500  West Madison Street, Suite 1400, Chicago, Illinois  60661;  7
World Trade Center, New York, New York, 10048; and 5670 Wilshire Boulevard,
Los Angeles, California 90036. Copies of such material can be obtained from
the  Public  Reference  Section of the Commission at Judiciary  Plaza,  450
Fifth  Street N.W., Washington, D.C. 20549 at prescribed rates. For further
information, the SEC maintains a website that contains reports,  proxy  and
information statements, and other information regarding reporting companies
at (http://www.sec.gov). We maintain a website at www.adcx.com.

ITEM 2.   PROPERTIES

     The Company's main offices are located at 2780 South Jones, Las Vegas,
Nevada. The facility is a leased 252 square foot facility utilized  in  the
following  manner: a) administrative offices, b) professional  offices,  c)
storage,  and  d)  developmental laboratory. The Company feels  the  office
space  is  adequate for its needs at this time and does not anticipate  the
need  for additional space within the following 12 months. The Company pays
rent  at  the  rate  of  $550  per month. The Company  has  other  tangible
property,  including computer equipment, proprietary software and biometric
prototype.

ITEM 3.   LEGAL PROCEEDINGS

     We  may  from  time  to  time  be involved in  routine  legal  matters
incidental to our business; however, at this point in time we are currently
not  involved  in  any litigation, nor are we aware of  any  threatened  or
impending litigation.

ITEM 4.   SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

     On  November 29, 2000, we held our annual stockholders meeting. At the
meeting  our stockholders voted to elect the current Board of Directors  to
serve  until the next annual meeting and until their successors are elected
and  qualified and reaffirmed Piercy, Bowler, Taylor & Kern as auditors for
fiscal 2001.

<PAGE>

PART II

ITEM 5.   MARKET  FOR  REGISTRANT'S COMMON EQUITY AND  RELATED  STOCKHOLDER
          MATTERS

     Our  Common Stock is traded in the over-the-counter securities  market
through  the National Association of Securities Dealers Automated Quotation
Bulletin  Board System, under the symbol "ANYD".  The following table  sets
forth  the  quarterly  high and low bid prices  for  our  Common  Stock  as
reported  by  the  National  Quotations Bureau.    The  quotations  reflect
inter-dealer  prices, without retail mark-up, markdown or  commission,  and
may not necessarily represent actual transactions.
<TABLE>

                     Average Low       Average High
<S>                  <C>               <C>
November 1999           $1.63              $3.38
December 1999           $1.25              $2.88
January 2000            $0.94              $3.38
February 2000           $1.56              $3.00
March 2000              $1.38              $3.01
April 2000              $0.78              $2.38
May 2000                $0.69              $1.44
June 2000               $0.59              $1.50
July 2000               $0.75              $2.63
August 2000             $0.69              $1.28
September 2000          $0.63              $1.03
October 2000            $0.22              $0.88
November 2000           $0.19              $0.44
December 2000           $0.09              $0.25
</TABLE>

Note: We started trading in November, 1999

     As  of  March 31, 2001, we had approximately 119 stockholders  of  the
12,895,303 shares outstanding.

     We  have  never  declared or paid dividends on our Common  Stock.   We
intend  to  follow a policy of retaining earnings, if any, to  finance  the
growth  of the business and do not anticipate paying any cash dividends  in
the foreseeable future.  The declaration and payment of future dividends on
the  Common Stock will be the sole discretion of the Board of Directors and
will   depend  on  our  profitability  and  financial  condition,   capital
requirements, statutory and contractual restrictions, future prospects  and
other factors deemed relevant.

ITEM 6.   MANAGEMENT'S  DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION  AND
          RESULTS OF OPERATIONS

      The  following discussion and analysis should be read in  conjunction
with our Financial Statements and the notes thereto appearing elsewhere  in
this document.

RISK FACTORS AND CAUTIONARY STATEMENTS

      This report contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange  Act  of  1934. Actual results and events could differ  materially
from  those  projected,  anticipated, or implicit, in  the  forward-looking
statements as a result of the risk factors set forth below and elsewhere in
this report.

<PAGE>

     With the exception of historical matters, the matters discussed herein
are  forward  looking  statements  that involve  risks  and  uncertainties.
Forward  looking  statements include, but are not  limited  to,  statements
concerning  anticipated  trends in revenues and net  income,  the  date  of
introduction   or  completion  of  our  products,  projections   concerning
operations  and  available  cash  flow. Our  actual  results  could  differ
materially  from the results discussed in such forward-looking  statements.
The  following  discussion  of  our  financial  condition  and  results  of
operations should be read in conjunction with our financial statements  and
the related notes thereto appearing elsewhere herein.

Overview

     The  Company, which was organized in November 1996, is a  Development
Stage  Enterprise,  engaged  in the business  of  marketing  services  and
products  related to the management of data based on biometric  individual
identification. The Company has a limited operating history  and  has  not
generated revenues from the sale of any products. The Company initiated  a
beta  testing system at the American Toxicology Institute and in  the  Las
Vegas Family Courts, which has been terminated. Until the installation  of
the system in Las Vegas, the Company's activities have been limited to the
development  of  prototypes, licensing U.S. patents, evaluating  biometric
equipment and analyzing the market conditions for the proprietary services
and  products.  Consequently, the Company has  incurred  the  expenses  of
start-up  and  patent licensing. Future operating results will  depend  on
many  factors,  including  the ability of the Company  to  raise  adequate
working capital, demand for the Company's services and products, the level
of   competition  and  the  Company's  ability  to  satisfy   governmental
regulations  and  deliver company services and products while  maintaining
quality  and  controlling costs. The Company's financial  statements  have
been prepared assuming the Company will continue as a going concern.

Results of Operations

     Period from January 1, 2000 to December 31, 2000

      The  first  years  of existence for the Company achieved  three  main
goals:  the formation of the Company's organization to pursue its  business
strategy,  development  of  a production model  and  achieving  the  public
company status to assist in funding the Company's objectives.

      Revenues. The Company is a development stage enterprise as defined in
Statement of Financial Accounting Standards No. 7, and has yet to  generate
any  revenues.  The Company is devoting substantially all  of  its  present
efforts  to:  (1)  developing  its medical  data  management  products  and
systems, (2) developing its market, and (3) obtaining sufficient capital to
commence full operations.

      General  and  Administrative. General and administrative,  legal  and
consulting  expenses  for the year ended December 31,  2000  were  $280,551
which  was  a  decrease from the $614,742 for the year ended  December  31,
1999.  This decrease was primarily the result of decreased expenses related
to the restructuring of the Company towards the licensing of its technology
or entering into strategic relationships.

      Research  and  Development. Research and  Development  expenses  were
$4,568,136 for the year ended December 31, 2000.

      Net  loss for the Company was $4,889,022 for the year ended  December
31,  2000  as compared to net loss of $919,389 for the year ended  December
31,  1999.  This increase was the result of increasing software development
and related additional expenses in attempting to enhance the technology  of
the Company.

<PAGE>

Liquidity and Capital Resources

     The  receipt of funds to the Company from Private Placement Offerings
and  loans obtained through private sources are anticipated to offset  the
near  term cash requirements of the Company. Since inception, the  Company
has  financed its cash flow requirements through debt financing,  issuance
of  common stock for cash and services, and minimal cash balances. As  the
Company expands its medical data management activities, it may continue to
experience  net  negative cash flows from operations, pending  receipt  of
sales  revenues,  and will be required to obtain additional  financing  to
fund operations through common stock offerings and bank borrowings to  the
extent necessary to provide its working capital.

      Over  the next twelve months, the Company is attempting to develop  a
revenue  stream by entering into strategic relationships or  licensing  its
technology  to  its  target  markets. The Company  believes  that  existing
capital  and  anticipated funds from operations will not be  sufficient  to
sustain  operations  in the next twelve months. Consequently,  the  Company
will  be  required  to  seek  additional capital  in  the  future  to  fund
operations   through  additional  equity  or  debt  financing   or   credit
facilities.  No  assurance  can  be  made  that  such  financing  would  be
available, and if available it may take either the form of debt or  equity.
In either case, the financing could have a negative impact on the financial
condition of the Company and its Shareholders.

     The  Company  hopes  to  enter into additional  funding  arrangements
through  strategic partnerships, merger, equity offering or debt offering.
Nothing has been secured as of this time.

     The  Company anticipates that it will incur operating losses  in  the
next  twelve  months.  The  Company's  lack  of  operating  history  makes
predictions  of  future  operating results  difficult  to  ascertain.  The
Company's prospects must be considered in light of the risks, expenses and
difficulties frequently encountered by companies in their early  stage  of
development,  particularly companies in new and rapidly  evolving  markets
such  as  bio-medical.  Such risks for the Company include,  but  are  not
limited  to,  an  evolving  and  unpredictable  business  model  and   the
management  of  growth. To address these risks, the  Company  must,  among
other  things, obtain a customer base, implement and successfully  execute
its  business and marketing strategy, continue to develop and upgrade  its
technology  and  products, provide superior customer  services  and  order
fulfillment, respond to competitive developments, and attract, retain  and
motivate  qualified personnel. There can be no assurance that the  Company
will be successful in addressing such risks, and the failure to do so  can
have  a  material  adverse  effect on the  Company's  business  prospects,
financial condition and results of operations.

ITEM 7.   FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

     See  Index  to Financial Statements and Financial Statement  Schedules
appearing on page F-1 through F-8 of this Form 10-KSB

ITEM 8.   CHANGES  IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING  AND
          FINANCIAL DISCLOSURE

     No Changes or disagreements to Report

<PAGE>

PART III

ITEM 9.   DIRECTORS  AND  EXECUTIVE OFFICERS OF THE REGISTRANT;  COMPLIANCE
          WITH SECTION 16(a) OF THE EXCHANGE ACT.

      The  following table sets forth the names, positions with the Company
and  ages of the executive officers and directors of the Company. Directors
will  be elected at the Company's annual meeting of shareholders and  serve
for  one  year or until their successors are elected and qualify.  Officers
are  elected  by  the Board and their terms of office are,  except  to  the
extent governed by employment contract, at the discretion of the Board.
<TABLE>
           Name               Age                Title
<S>                           <C>    <C>
James E. Beecham, MD          52     Chairman of the Board
William M. Somers, OD         54     Director
</TABLE>

Duties, Responsibilities and Experience

James E. Beecham, MD. Founded Anonymous Data Corporation and has served as
Chairman  of the Board since inception in November of 1996. From  1990  to
present  Dr.  Beecham  has  been  a  Physician/Pathologist  at  Laboratory
Medicine  Consultants  Laboratories,  Inc.  Dr.  Beecham  served  as  Vice
President  of Laboratory Medicine Consultants Laboratories, Inc.,  a  full
service medical laboratory located in Las Vegas, Nevada from its inception
until it's sale in 1997. Dr. Beecham is a member of the Board of Directors
and  full  partner  in Laboratory Medicine Consultants,  Ltd.,  a  medical
practice  consisting of 12 pathologists located in Las Vegas, Nevada.  Dr.
Beecham received his medical degree from the University of Florida  School
of  Medicine  in  1973. He has been engaged in the full time  practice  of
medicine in the specialty of Pathology since his completion of a residency
at  the University of North Carolina and University of Washington in 1978.
Dr.   Beecham  spends  approximately  25%  of  his  time  on  ADC  related
activities.

William  M. Somers, OD has served as Director of Anonymous Data Corporation
since  November, 1998. From 1994 until present William Somers, a Doctor  of
Optometry  has  maintained a full time optometry  practice  in  Las  Vegas,
Nevada.  He  has  held numerous committee positions throughout  his  career
including  the Medicare Carrier Advisory Committee, the Nevada  chapter  of
the American Optometric Association and advisory board committee member and
spokesman for Vistakon (Johnson & Johnson contact lenses). He received  his
optometry degree from the Southern California College of Optometry.

LIMITATION OF LIABILITY OF DIRECTORS

     Pursuant  to  the  Nevada General Corporation  Law,  our  Articles  of
Incorporation  exclude  personal liability for our Directors  for  monetary
damages  based  upon any violation of their fiduciary duties as  Directors,
except  as  to  liability for any breach of the duty of  loyalty,  acts  or
omissions  not in good faith or which involve intentional misconduct  or  a
knowing violation of law, or any transaction from which a Director receives
an  improper personal benefit. This exclusion of liability does  not  limit
any  right which a Director may have to be indemnified and does not  affect
any Director's liability under federal or applicable state securities laws.
We  have agreed to indemnify our directors against expenses, judgments, and
amounts  paid in settlement in connection with any claim against a Director
if  he  acted in good faith and in a manner he believed to be in  our  best
interests.

<PAGE>



BOARD OF DIRECTORS COMMITTEES AND COMPENSATION

Compensation Committee Interlocks and Insider Participation

     The  Board of Directors does not have a Compensation Committee.  James
Beecham, President, oversaw the compensation of our executive officers.
Board of Director's Report on Executive Compensation

     General.   As  noted above, our Board of Directors  does  not  have  a
Compensation  Committee  and, accordingly, during  the  fiscal  year  ended
December  31, 2000, the Board of Directors, through the President, reviewed
and approved the compensation of our executive officers.

     Overall   Policy;  Significant  Factors.   During  fiscal  2000,   the
compensation  decisions made by the Board of Directors in  respect  of  our
executive orders were influenced by three major factors.  First, our start-
up  nature brings with it all of the normal capital requirements to sustain
growth,  therefore  certain  stock compensation  was  granted  in  lieu  of
salaries,  commissions and for services rendered.   This  practice  may  be
extended into the future on a case by case basis and accordingly filed with
the Securities and Exchange Commission.  Finally, as we continue to mature,
certain  additions  to the executive staff will be  required.   As  we  are
required to seek talent in outside market, we will be required to provide a
competitive compensation package.

     As  overall policy, however, the Board continues to believe that long-
term  compensation  tied  to  the  creation  of  stockholder  value  should
constitute a significant component of the compensation to be earned by  our
executive  officers.   In this respect, it will be the  Board's  policy  to
attempt   to  restrain  base  cash  compensation  (subject  to  competitive
pressures),  while  providing  the incentive  for  Management  to  increase
stockholder  value by providing such officers with significant  numbers  of
market-price stock that will not confer value upon the officers unless  and
until the Company's share price rises.  The Board of Directors expects that
stock  options will constitute a significant component of the  compensation
package provided to executive officers.

     The  Board believes that cash bonuses are, at times, appropriate based
upon  the  performance of the Company's business compared to  our  internal
expectations and general business conditions.

ITEM 10.  EXECUTIVE COMPENSATION

      The following table sets forth the cash compensation of the Company's
executive  officers  and directors during each of the  fiscal  years  since
inception of the Company. The remuneration described in the table does  not
include  the  cost  to  the  Company of benefits  furnished  to  the  named
executive  officers,  including premiums for  health  insurance  and  other
benefits  provided to such individual that are extended in connection  with
the conduct of the Company's business. The value of such benefits cannot be
precisely  determined,  but  the executive officers  named  below  did  not
receive  other compensation in excess of the lesser of $50,000  or  10%  of
such officer's cash compensation.

<PAGE>
<TABLE>
Summary Compensation Table
                                                            Long Term
                              Annual Compensation         Compensation

                                                       Restricted
Name and Principal                       Other Annual     Stock
     Position       Year  Salary  Bonus  Compensation    (2)(3)    Options
<S>                 <C>   <C>     <C>    <C>           <C>        <C>
James   E.  Beecham
(1)                 1996    -0-    -0-        -0-          -0-       -0-
James E. Beecham    1997    -0-    -0-        -0-          -0-       -0-
James E. Beecham    1998    -0-    -0-        -0-          -0-       -0-
James E. Beecham    1999    -0-    -0-        -0-          -0-       -0-
James E. Beecham    2000    -0-    -0-        -0-          -0-       -0-
William M. Somers   1998    -0-    -0-        -0-         1,000      -0-
William M. Somers   1999    -0-    -0-        -0-         9,000      -0-
William M. Somers   2000    -0-    -0-        -0-        100,000     -0-
</TABLE>

(1)  Beecham purchased 6,000,000 shares of restricted stock in the Company
     at $.02 per share as the result of his Pre-Incorporation Agreement
     with the Company.

Compensation of Directors

   All  directors  will  be reimbursed for expenses incurred  in  attending
   Board or committee meetings.

Stock Option Plan

     The  following  descriptions  apply to stock  option  plan  which  the
Company has adopted; however, no options have been granted as of this date.

     The Company reserved for issuance an aggregate of 1,500,000 shares  of
common  stock under a Stock Option Plan (the "Stock Option Plan") and  Non-
Employee Directors' Plan described below (the "Directors' Plan") which  has
been  adopted  by  the  Company.  These plans  are  intended  to  encourage
directors,  officers, employees and consultants of the Company  to  acquire
ownership  of  common stock.  The opportunity so provided  is  intended  to
foster  in participants a strong incentive to put forth maximum effort  for
the  continued  success  and growth of the Company,  to  aid  in  retaining
individuals  who  put forth such efforts, and to assist in  attracting  the
best available individuals to the Company in the future.

     Officers  (including  officers  who  are  members  of  the  Board   of
Directors),  directors  (other than members of the Stock  Option  Committee
(the "Committee") to be established to administer the Stock Option Plan and
the Directors' Plan) and other employees and consultants of the Company and
its subsidiaries (if established) will be eligible to receive options under
the  planned  Stock Option Plan.  The Committee will administer  the  Stock
Option  Plan  and  will  determine those persons to whom  options  will  be
granted, the number of options to be granted, the provisions applicable  to
each  grant and the time periods during which the options may be exercised.
No  options  may  be  granted more than ten years after  the  date  of  the
adoption of the Stock Option Plan.

     Unless  the  Committee, in its discretion, determines otherwise,  non-
qualified stock options will be granted with an option price equal  to  the
fair  market value of the shares of common stock to which the non-qualified
stock  option  relates on the date of grant.  In no event  may  the  option
price  with  respect to an incentive stock option granted under  the  Stock
Option  Plan  be  less than the fair market value of such common  stock  to
which  the  incentive stock option relates on the date the incentive  stock
option is granted.

<PAGE>

     Each  option  granted under the Stock Option Plan will be  exercisable
for  a  term  of not more than ten years after the date of grant.   Certain
other restrictions will apply in connection with this Plan as to when  some
awards  may be exercised.  In the event of a change of control (as  defined
in  the Stock Option Plan), the date on which all options outstanding under
the  Stock  Option  Plan  may  first  be  exercised  will  be  accelerated.
Generally, all options terminate 90 days after a change of control.

ITEM 11.  SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

Security Ownership of Certain Beneficial Owners.

      The following table sets forth certain information as of December 31,
2000  with respect to the beneficial ownership of common stock by (i)  each
person  who to the knowledge of the Company, beneficially owned or had  the
right  to  acquire more than 5% of the Outstanding common stock, (ii)  each
director  of  the Company and (iii) all executive offices and directors  of
the Company as a group.
<TABLE>

                                          Number          Percent
     Name of Beneficial Owner (1)        of Shares     Of Class (2)
<S>                                     <C>           <C>
 James E. Beecham, MD                       5,154,643            40%
 William M. Somers, OD                        110,000             0%
 All Directors & Officers as a Group        5,264,643            40%
</TABLE>

(1)  As used in this table, "beneficial ownership" means the sole or shared
     power to vote, or to direct the voting of, a security, or the sole  or
     shared investment power with respect to a security (i.e., the power to
     dispose of, or to direct the disposition of, a security).  In addition, for
     purposes  of this table, a person is deemed, as of any date,  to  have
     "beneficial ownership" of any security that such person has the right to
     acquire within 60 days after such date.
(2)  Figures are rounded to the nearest percentage. Less than 1% is
     reflected as 0%.

ITEM 12.  CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

PreIncorporation  Agreement.  On the 1st of November,  1996,  the  Company
entered  into an agreement with James Beecham, MD, wherein Beecham  agreed
to  provide  exclusively to the Company an option to enter into  a  formal
License  Agreement.  The Pre-Incorporation Agreement provided  that  James
Beecham  would  receive 6,000,000 shares of common stock  at  a  price  to
Beecham  of  $0.02  per  share to be paid over two  years.  The  agreement
recited  that  the  option  was  the  only  asset  of  the  to  be  formed
corporation.

License  Agreement. On May 14 1998, the Company entered into an "Exclusive
Licensee  Territorial Agreement" for two U.S. patents relating to  medical
biometrics  with Dr. James Beecham, Chairman of the Company,  in  exchange
for  future royalties in the amount of three percent (3%) of the first $10
million  gross revenues to the Company from the manufacture, use, sale  or
operation of the Products and Services, two percent (2%) of gross revenues
which exceed $10 million but are under $25 million and one percent (1%) of
gross  revenues which exceed $25 million. We are required  to  produce  at
least $1 million in gross revenues within seven (7) years or the agreement
will   terminate.  A  disinterested  Company  senior  management  official
approved  the agreement which was then ratified by the Board of Directors.
The   Company  believes  the  agreement  is  commercially  reasonable  and
generally  equivalent  to  what  a  third  party  would  receive  with  no
affiliation.

<PAGE>

On February 1, 1999, the agreement was amended to include worldwide rights
on  a country by country basis and extend the term of the agreement to May
14, 2016.

Officer  Loans.  In November 1999, the Chairman loaned the Company  $51,000
at 10% annually.  Interest payments are due annually with principal balance
due  in  2004. As of December 31, 2000 the Chairman's loans to the  Company
had  a  balance of $376,906. During 2000, the Company issued 137,134 shares
of  its common stock, valued at market price, to the Chairman in payment of
$30,000 in interest expense.

ITEM  13. EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND  REPORTS ON FORM 8-K

(a)  Documents filed as part of this Report

     1.   Financial Statements:

             Independent Auditors  Report                               F-1
             Financial Statements:
               Balance Sheet                                            F-2
               Statement of Operation                                   F-3
               Statement of Changes in Stockholders'                    F-4
               Statement of Cash Flows                                  F-5
               Notes to Consolidated Financial Statements         F-6 - F-7

               All schedules are omitted because they are not applicable or
          the  required information is shown in the consolidated  financial
          statements or notes thereto.

     2.   Exhibits

          See Index to Exhibits on page E-1

(b)  Reports on Form 8-K

          1.   During the fiscal year 2000, the Company filed the following
          8-Ks.

               8-K filed February 1, 2000

          2.    Subsequent to the end of the fiscal year, the Company filed
          the following reports on Form 8-K

          8-K filed March 22, 2001

<PAGE>

                                SIGNATURES

      Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange  Act  of 1934, the registrant has duly caused this  report  to  be
signed on our behalf by the undersigned, thereunto duly authorized.

ANONYMOUS DATA CORPORATION                   DATED: April 30, 2001



By:/s/ James Beecham
     James Beecham
     President


      Pursuant to the requirements of the Securities Exchange Act of  1934,
this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.

Signature                     Title                         Date

/s/ James Beecham             President           April 30, 2001
James Beecham

/s/ William Somers            Director            April 30, 2001
William Somers

<PAGE>

                             INDEX TO EXHIBITS
                              ITEM 13 (a) (2)

 Exhibit                             Description
 Number
 (1)      N/A
 (2)      N/A
 (3)(i)   Articles of Incorporation
          (a) Articles of Incorporation of Anonymous Data Corporation*
          (b) Articles  of  Incorporation, as amended  for  Anonymous  Data
               Corporation, a Nevada corporation*
          (c) Articles  of  Incorporation, as amended  for  Anonymous  Data
               Corporation, a Nevada corporation*
 (3)(ii)  Bylaws
          (a) Bylaws of Anonymous Data Corporation*
          (b) Bylaws,  as amended for Anonymous Data Corporation, a  Nevada
               corporation*
 (4)      Instruments defining the rights of security holders:
 (4)(i)   (a) Articles  of Incorporation for Anonymous Data Corporation,  a
               Nevada Corporation *
          (b) Bylaws of Anonymous Data Corporation, a Nevada Corporation*
 (5)      N/A
 (8)      N/A
 (9)      N/A
 (10)     Material Contracts
          (a) Pre Incorporation Agreement with James Beecham*
          (b) Stock Option Plan*
          (c) Exclusive  Licensee  Territorial  Agreement  with  James   E.
               Beecham*
          (d))Amendment  to  Licensee Territorial Agreement with  James  E.
               Beecham*
          (e) Office Lease Agreement (filed herewith)
          (f) Contract For ADCnet Beta Project (filed herewith)
          (g) Memorandum   of   Understanding   between   Anonymous    Data
               Corporation  and American Toxicology Institute, Inc.  (filed
               herewith)
          (h) Memorandum   of   Understanding   between   Anonymous    Data
               Corporation and VSOP (filed herewith)
 (11)     Contained  in the Notes to the Financial Statements on  page  F-6
           (filed herewith)
 (13)     N/A
 (15)     N/A
 (16)     N/A
 (17)     N/A
 (18)     N/A
 (19)     N/A
 (20)     Proxy for Annual Meeting of Stockholders**
 (21)     N/A
 (22)     N/A
 (23)     N/A
 (24)     N/A
 (25)     N/A
 (26)     N/A
 (99)     Cautionary Statement Regarding Forward Looking Statements  (filed
          herewith)
*    Incorporated by reference. (filed with Form 10SB on March 10, 1999)
**   Incorporated by reference. (filed on form DEF 14A on October 26, 2000)
<PAGE>

                       INDEPENDENT AUDITORS' REPORT




Board of Directors
Anonymous Data Corporation
Las Vegas, Nevada

We  have  audited  the  balance  sheets of Anonymous  Data  Corporation  (a
development  stage enterprise) as of December 31, 2000 and  1999,  and  the
related  statements of operations, stockholders' equity and cash flows  for
the  years then ended and for the period from inception (November 15, 1996)
through   December   31,   2000.  These  financial   statements   are   the
responsibility  of  the  Company's management.  Our  responsibility  is  to
express an opinion on these financial statements based on our audits.

We  conducted  our  audits in accordance with generally  accepted  auditing
standards. Those standards require that we plan and perform the  audits  to
obtain reasonable assurance about whether the financial statements are free
of  material  misstatement.  An audit includes examining, on a test  basis,
evidence   supporting  the  amounts  and  disclosures  in   the   financial
statements.   An  audit  also includes assessing the accounting  principles
used  and  significant estimates made by management, as well as  evaluating
the  overall financial statement presentation.  We believe that our  audits
provide a reasonable basis for our opinion.

In  our opinion, the financial statements referred to above present fairly,
in  all  material  respects,  the  financial  position  of  Anonymous  Data
Corporation  as  of December 31, 2000 and 1999, its results of  development
stage operations and its cash flows for the periods presented in conformity
with generally accepted accounting principles.

The  accompanying  balance  sheets have been  prepared  assuming  that  the
Company will continue as a going concern.  As discussed in Notes 1  and  3,
the Company's ability to commence operations and realize its investments in
assets  is dependent upon obtaining additional sources of capital  to  fund
the  successful  completion of its equipment and software  development  and
marketing of its products.  This condition raises substantial doubt  as  to
the Company's ability to continue as a going concern. Management's plans in
regard to this matter are described in Note 3. The financial statements  do
not  include  any  adjustments that might result from the outcome  of  this
uncertainty.



Las Vegas, Nevada
March 30, 2001

<PAGE>
<TABLE>
ANONYMOUS DATA CORPORATION
(A Development Stage Enterprise)
BALANCE SHEETS
DECEMBER 31, 2000 AND 1999


                                                      2000           1999
<S>                                               <S>          <S>
ASSETS

Current assets
  Cash                                                             $3,939
  Prepaid expenses                                $161,777

Furniture and equipment, net                        60,986         89,225
Unamortized patent costs                           118,307         96,038
                                                  -----------------------
                                                  $341,070       $189,202
                                                  =======================
</TABLE>
<TABLE>
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIENCY)
<S>                                               <C>          <C>
Current liabilities:
  Accounts payable                                 $23,024        $37,569
  Accrued payroll taxes                                             7,089
  Accrued interest, related party                   12,791          5,100
  Capitalized lease obligation                                      1,528
                                                   ----------------------
                                                    35,815         51,286
Long-term debt, related party                      376,906         51,000
                                                   ----------------------
                                                   412,721        102,286
                                                   ----------------------

Stockholder's equity (deficiency):

  Common stock, $.001 par, 100,000,000
     shares authorized, 12,895,303 and
     9,438,160 shares issued and outstanding        12,895          9,438

  Preferred stock, $.001 par, 25,000,000
     shares authorized, none issued and
     outstanding

  Additional paid-in capital                     6,419,374      1,692,376
  Accumulated deficit                          (6,503,920)    (1,614,898)
                                               --------------------------
                                                  (71,651)         86,916
                                               --------------------------
                                                  $341,070       $189,202
                                               ==========================
</TABLE>
<PAGE>
<TABLE>
ANONYMOUS DATA CORPORATION
(A Development Stage Enterprise)
STATEMENTS OF OPERATIONS
FOR THE YEARS ENDED DECEMBER 31, 2000 AND 1999 AND FOR THE PERIOD FROM
INCEPTION (NOVEMBER 15, 1996) THROUGH DECEMBER 31, 2000


                                        Year Ended December      From
                                                31,            Inception
                                                                Through
                                                               December
                                                                  31,
                                         2000         1999       2000
<S>                                   <C>            <C>      <C>
Expenses:
  Research and development            $4,568,136     $281,438  $5,379,408
  Administrative                         280,551      614,742   1,046,853
  Depreciation                            38,344       26,462      74,568
  Interest, substantially all to the
principal shareholder                     37,991        5,785      48,129
                                       ----------------------------------
                                       4,925,022      928,427   6,548,958
                                       ----------------------------------
Income:
  Donated office space                    36,000                   36,000
  Interest                                              2,109       2,109
  Other                                                 6,929       6,929
                                       ----------------------------------
                                          36,000        9,038      45,038
                                       ----------------------------------
Net loss                              $4,889,022     $919,389  $6,503,920
                                      ===================================

Loss per share                             $0.42        $0.10       $0.61
                                      ===================================
Weighted average number of shares
outstanding                           11,525,789    9,325,932  10,708,420
                                      ===================================
</TABLE>
<PAGE>
<TABLE>


ANONYMOUS DATA CORPORATION
(A Development Stage Enterprise)
STATEMENT OF STOCKHOLDERS' EQUITY
FOR THE YEARS ENDED DECEMBER 31, 2000 AND 1999 AND FOR THE PERIOD FROM
INCEPTION (NOVEMBER 15, 1996) THROUGH DECEMBER 31, 1998




                                                              Additional
                                            Common stock        paid-in
                                           Shares   Par value   capital
<S>                                     <C>         <C>       <C>
Common shares issued from
inception (November 15, 1996)
through December 31, 1998, to:
  Founding shareholder for stock
subscription receivable                  6,000,000    $6,000     $114,000
  Officer and director for expenses      1,023,000     1,023       43,631
  Officers and directors for services       67,000        67       66,933
  Employees for services                   253,500       254       22,946
  Employees for cash                       175,000       175        3,325
  Consultants for services                 698,200       698      379,002
  Others for cash                           93,300        93       93,207
  Shareholder in payment of advances        50,000        50       49,950
  Officer and directors for payment of
offering costs                             134,000       134      133,866

Payment of stock subscription
receivable from founding shareholder
                                         --------------------------------
Net loss
Balances, December 31, 1998              8,494,000     8,494      906,860

Common shares issued in 1999 to:
  Officers and directors for services      114,500       115      114,385
  Consultants for services                 266,710       266      286,444
  Others for cash                          542,950       543      542,407
  Officer and directors for payment of
offering costs                              20,000        20       19,980
  Less offering costs                                           (177,700)
Net loss
                                         --------------------------------
Balances, December 31, 1999              9,438,160     9,438    1,692,376

Common shares issued in 2000:
  For services:
  Officers and directors                   100,000       100       31,150
  Employees                                 15,000        15       29,985
  Consultants                            3,205,000     3,205    4,636,000
  Principal shareholder in payment of
interest expense                           137,143       137       29,863
Net loss
                                        ---------------------------------
Balances, December 31, 2000             12,895,303   $12,895   $6,419,374
                                        =================================
</TABLE>
<PAGE>
<TABLE>
ANONYMOUS DATA CORPORATION
(A Development Stage Enterprise)
STATEMENT OF STOCKHOLDERS' EQUITY
FOR THE YEARS ENDED DECEMBER 31, 2000 AND 1999 AND FOR THE PERIOD FROM
INCEPTION (NOVEMBER 15, 1996) THROUGH DECEMBER 31, 1998 (CONTINUED)


                                                    Deficit
                                                  accumulated
                                         Stock       during
                                      subscription  development
                                      reveivable      stage        Total
<S>                                   <C>         <C>           <C>
Common shares issued from
inception (November 15, 1996)
through December 31, 1998, to:
  Founding shareholder for stock
subscription receivable               $(120,000)
  Officer and director for expenses                                $44,654
  Officers and directors for                                        67,000
services
  Employees for services                                            23,200
  Employees for cash                                                 3,500
  Consultants for services                                         379,700
  Others for cash                                                   93,300
  Shareholder in payment of advances                                50,000
  Officer and directors for payment
of offering costs                                                  134,000

Payment of stock subscription
receivable from founding shareholder     120,000                   120,000
Net loss                                             (695,509)   (695,509)
                                         ---------------------------------
Balances, December 31, 1998                    -     (695,509)     219,845

Common shares issued in 1999 to:
  Officers and directors for                                       114,500
services
  Consultants for services                                         286,710
  Others for cash                                                  542,950
  Officer and directors for payment
of offering costs                                                   20,000
  Less offering costs                                            (177,700)
Net loss                                             (919,389)   (919,389)
                                        ----------------------------------
Balances, December 31, 1999                    -   (1,614,898)      86,916

Common shares issued in 2000:
  For services:
  Officers and directors                                            31,250
  Employees                                                         30,000
  Consultants                                                    4,639,205
  Principal shareholder in payment
of interest expense                                                 30,000
Net loss                                           (4,889,022)  (4,889,022)
                                       ------------------------------------
Balances, December 31, 2000                   $-  $(6,503,920)    $(71,651)
                                       ====================================
</TABLE>
<PAGE>
<TABLE>

ANONYMOUS DATA CORPORATION
(A Development Stage Enterprise)
STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED DECEMBER 31, 2000 AND 1999 AND FOR THE PERIOD FROM
INCEPTION (NOVEMBER 15, 1996) THROUGH DECEMBER 31, 2000


                                           Year Ended             From
                                       2000         1999       Inception
                                                                Through
                                                              December 31,
                                                                  2000
<S>                               <C>           <C>         <C>
Operating activities:
  Net loss                         $(4,889,022)   $(919,389)  $(6,503,920)
  Depreciation                           38,344       26,462        74,568
  Expenses paid with stock            4,730,455      401,210     5,646,219
  Change in operating assets:
  (Increase) decrease in prepaid
expenses                              (161,777)        1,000     (161,777)
  Change in operating liabilities:
  Increase (decrease) in accounts
payable                                (14,545)       31,699        24,473
  Increase (decrease) in accrued
expenses                                (7,089)        5,640       (1,449)
  Increase in accrued interest            7,691        5,100        12,791
                                   ---------------------------------------
  Net cash used in operating
activities                            (295,943)    (448,278)     (909,095)
                                   ---------------------------------------
Investing activities:
  Purchase of equipment                (10,105)    (102,708)     (130,308)
  Patent costs                         (22,269)     (35,400)     (118,307)
                                   ---------------------------------------
  Net cash used in investing
activities                             (32,374)    (138,108)     (248,615)
                                   ---------------------------------------
Financing activities:
  Payment of stock subscription
receivable by founding shareholder                                 120,000
  Sale of common stock                               542,950       639,750
  Offering costs paid with cash                     (13,700)      (23,700)
  Loan from founding shareholder        325,906       51,000       426,906
  Other                                 (1,528)      (3,718)       (5,246)
                                   ---------------------------------------
  Net cash provided by financing
activities                              324,378      576,532     1,157,710
                                   ---------------------------------------
Net decrease in cash                    (3,939)      (9,854)

Cash, beginning                           3,939       13,793
                                   ---------------------------------------

Cash, ending                                 $-       $3,939            $-
                                   =======================================
Non-cash financing and investing
activities:
  Exchange of stock for offering
costs                                                $20,000      $154,000
                                                 =========================
  Settlement of stockholder
advances with stock                                                $50,000
                                                              ============
</TABLE>
<PAGE>

ANONYMOUS DATA CORPORATION
(A Development Stage Enterprise)
NOTES TO FINANCIAL STATEMENTS
FROM INCEPTION (NOVEMBER 15, 1996) THROUGH DECEMBER 31, 2000
________________________________________________________________________

1.   Summary of significant accounting policies:

Nature  of  business.  The Company is a development stage  enterprise  and,
therefore,  as of December 31, 2000, has not commenced business operations.
The  Company  was  incorporated  in 1996  for  the  purpose  of  developing
biometric  equipment  and related software to store and  retrieve  data  in
connection with personal identification. The Company is in the research and
development  phase  of testing its technical equipment and  software.   The
Company's future operations could be affected by adverse changes  in  local
and national economic conditions.  (See Note 3.)

Use of estimates.  Timely preparation of financial statements in conformity
with  generally accepted accounting principles requires management to  make
estimates  and  assumptions that affect reported amounts  and  disclosures,
some of which may require revision in future periods.

Equipment  and depreciation.  Equipment is stated at cost. Depreciation  is
provided  by an accelerated method over the estimated useful lives  of  the
assets.

Stock  compensation  awards.  The Company has adopted Financial  Accounting
Standards  Board Statement No. 123 Accounting for Stock-Based Compensation,
for valuing compensatory stock and option awards. (See Note 6.)

Patent  costs.   Costs  associated with patents  and  patents  pending  are
capitalized and will be amortized based on the lives of the patents granted
once  business  operations commence.  In the event patent applications  are
denied or abandoned, such costs are written off.

Advertising  costs.   Advertising  costs are  expensed  when  incurred  and
totaled  $29,855, $57,546, and $127,077 for 2000, 1999 and  the  cumulative
period from inception.

Loss  per share.  Loss per share is computed based on the weighted  average
number of shares outstanding for the periods presented.

2.   Related party transactions:

In  May  1998,  Dr. James E. Beecham (Chairman of the Board  of  Directors,
majority shareholder and president of the Company) licensed to the  Company
the rights associated with two U.S. patents. In February 1999, the licenses
were amended. The licenses will continue until May 14, 2016. The Company is
required to produce $1 million in gross revenues within the first  7  years
or  the  licenses  will terminate. In consideration for the  assignment  of
rights,  Dr. Beecham will receive a royalty of 3% of the first $10 million,
2% of $10 to $25 million, and 1% in excess of $25 million in gross revenues
to the Company from the manufacture, use, sale or operation of the products
and  services.  Accordingly no value has been assigned the license  in  the
accompanying financial statements.

The  Chairman  has made loans to the Company, on which the balance  due  at
December  31,  2000, was $376,906.  Payments of interest  at  10%  are  due
annually with the principal due in its entirety in 2004.  During 2000,  the
Company issued 137,134 shares of its common stock, valued at market  price,
to the Chairman in payment of $30,000 in interest expense.

During  2000, the Company issued 100,000 shares of its common stock to  its
officers/directors,  15,000 shares of its common  stock  to  employees  and
3,205,000 shares of its common stock to consultants, valued at market price
as of the transaction dates, as compensation for services.

3.   Going concern contingency:

Since   its  inception,  the  Company  has  accumulated  development  stage
operating  losses  in  excess of $6.5 million.   Its  ability  to  complete
certain research projects and the development of its equipment and software
is  dependent  upon  obtaining additional equity or  debt  financing.  This
condition could prevent the Company from commencing business operations and
continuing  as  a  going concern.  The balance sheets, however,  have  been
prepared assuming the Company will continue as a going concern, and reflect
no adjustments that might result from the outcome of this uncertainty.

<PAGE>

ANONYMOUS DATA CORPORATION
(A Development Stage Enterprise)
NOTES TO FINANCIAL STATEMENTS
FROM INCEPTION (NOVEMBER 15, 1996) THROUGH DECEMBER 31, 2000
________________________________________________________________________

Because of this uncertainty, no effect has been given in the balance sheets
to  any future income tax benefit of the development stage operating losses
recorded  to  date.   The  Company has a net  operating  loss  carryforward
expiring in year 2020 available to reduce future income tax expense in  the
amount of approximately $6,500,000.

Management  expects  to  raise additional equity capital  by  offering  its
common  stock  for  sale  to  investors through  private  placement  or  by
registration with the SEC under the Securities Act of 1933 or  obtain  debt
financing  to  complete  its research projects, to  finish  developing  its
equipment  and  software  and  to obtain the  related  additional  patents.
Management  expects  that the Company's medical data management  equipment,
when  completed,  will  have  a wide range of  applications.   Management's
possible inability to effectively implement its plans could have a material
and  adverse  effect upon the Company's business, financial  condition  and
future operations.

4.   Stock option plan:

The  Company  adopted a stock option plan which reserves  for  issuance  an
aggregate  of  1,500,000  shares of common stock.   No  options  have  been
granted to date.